EACTS 2023 Late-Breakers
At Artivion, we partner with cardiovascular surgeons to develop cutting-edge technologies to treat patients with aortic diseases. We are committed to collecting and sharing clinical data related to our aortic-centered technologies to further the science of aortic disease treatment. We are excited to announce the release of post-approval study findings for On-X® Aortic Heart Valves and the interim results for our PERSEVERE IDE Study for the AMDS Hybrid Prosthesis, which were presented at the 37th EACTS Annual Meeting on October 5th.
On-X Aortic Heart Valve PAS Results
|
PERSEVERE US IDE Interim Results |
